Much of this decline can be attributed to the company’s weaker-than-expected performance ... citing issues with a third-party supplier. Given the substantial fall in Regeneron’s stock price ...

We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ... relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the ...

The S&P 500 added 1% on Friday, June 6, as a strong jobs report pointed to resilience in the labor market despite ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc. (MA), Verizon ...

The outbreak occurred in a flock of 190 backyard poultry birds in the district of Birzgales, Paris-based WOAH said in a notice, citing Latvian authorities. Vera shares skyrocket as kidney disease drug ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

On Monday, RBC Capital analysts reiterated their Sector Perform rating for Regeneron Pharmaceuticals stock (NASDAQ:REGN), maintaining a ... despite noting challenges with itepekimab and ongoing issues ...